Nilsson B, Grossberger D, Nilsson Ekdahl K, Riegert P, Becherer D J, Nilsson U R, Lambris J D
Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden.
Biochem J. 1992 Mar 15;282 ( Pt 3)(Pt 3):715-21. doi: 10.1042/bj2820715.
In previous studies a subset of complement-component-C3 (C3) epitopes, C3(D), expressed in denatured and surface-bound C3 and C3 fragments, has been described. These epitopes were detected by antibodies raised against denatured C3. In the present study we used a cDNA expression strategy to localize epitopes recognized by monoclonal and polyclonal anti-C3(D) antibodies. First, DNAse I digestion of C3 cDNA was used to generate 200-300 bp fragments. These cDNA fragments were expressed as beta-galactosidase-C3 fusion proteins using the lambda gt11 vector. The fusion proteins were tested by Western-blot analysis for reactivity with monoclonal and polyclonal anti-C3 antibodies, and the location of the epitopes were determined by sequencing the cDNA fragments. Affinity-purified polyclonal anti-C3(D) antibodies specific for denatured C3 reacted strongly with the C3 fusion fragments corresponding to segments of the 40 kDa subunit of C3c (residues 1477-1510) and the C3d fragment (residues 1117-1155 and 1234-1294) of C3. Adsorption of the polyclonal antibodies with a mixture of EAC3b and EAC3bi (degradation fragments of C3 bound to sheep erythrocytes) abolished binding to fusion proteins spanning the C3d region, but not the 40 kDa fragment of C3c. No effect was seen with the corresponding soluble C3 fragments. The monoclonal anti-C3(D) antibodies (mAbs) 7D326.1 and 7D331.1, specific for EAC3b and EAC3bi, bound to a fusion protein corresponding to amino acid residues 1312-1404, whereas mAb 7D9.2, specific for EAC3d, reacted with a fusion protein spanning amino acid residues 1082-1118. mAbs 4SD11.1 and 4SD18.1, which did not bind to any physiological C3 fragment, detected a fusion protein covering residues 1477-1510. In summary, the segments of C3 represented by amino acid residues 1082-1118, 1117-1155, 1234-1294 and 1312-1404 accommodate C3(D) epitopes that are expressed by erythrocyte-bound C3 fragments, but not by the corresponding fluid-phase fragment, whereas the segments spanning residues 973-1026 and 1477-1510 contain C3(D) epitopes that are exposed exclusively in denatured C3 and therefore hidden in physiological fragments of the protein.
在先前的研究中,已经描述了补体成分C3(C3)表位的一个亚组,即C3(D),它在变性的和表面结合的C3及C3片段中表达。这些表位通过针对变性C3产生的抗体来检测。在本研究中,我们使用cDNA表达策略来定位单克隆和多克隆抗C3(D)抗体识别的表位。首先,用DNA酶I消化C3 cDNA以产生200 - 300 bp的片段。这些cDNA片段使用λgt11载体表达为β - 半乳糖苷酶 - C3融合蛋白。通过蛋白质印迹分析测试融合蛋白与单克隆和多克隆抗C3抗体的反应性,并通过对cDNA片段测序来确定表位的位置。对变性C3特异的亲和纯化多克隆抗C3(D)抗体与对应于C3c的40 kDa亚基片段(残基1477 - 1510)和C3的C3d片段(残基1117 - 1155和1234 - 1294)的C3融合片段强烈反应。用EAC3b和EAC3bi(结合到绵羊红细胞上的C3降解片段)的混合物吸附多克隆抗体,消除了与跨越C3d区域的融合蛋白的结合,但不影响与C3c的40 kDa片段的结合。对相应的可溶性C3片段没有影响。对EAC3b和EAC3bi特异的单克隆抗C3(D)抗体7D326.1和7D331.1与对应于氨基酸残基1312 - 1404的融合蛋白结合,而对EAC3d特异的单克隆抗体7D9.2与跨越氨基酸残基1082 - 1118的融合蛋白反应。不与任何生理性C3片段结合的单克隆抗体4SD11.1和4SD18.1检测到一个覆盖残基1477 - 1510的融合蛋白。总之,由氨基酸残基1082 - 1118、1117 - 1155、1234 - 1294和1312 - 1404代表的C3片段容纳了由红细胞结合的C3片段表达但不由相应液相片段表达的C3(D)表位,而跨越残基973 - 1026和1477 - 1510的片段包含仅在变性C3中暴露因此在该蛋白的生理性片段中隐藏的C3(D)表位。